Population impact of Vi capsular polysaccharide vaccine

Expert Review of Vaccines

Volumn 9, Issue 5, 2010, Pages 485-496

  Khan, M Imran ^a   Ochiai, R Leon ^a   Clemens, John D ^a  

^a International Vaccine Institute   (South Korea)

Author keywords

Effectiveness; Efficacy; Fever; Salmonella Typhi; Typhoid; Vi polysaccharide

Indexed keywords

AMPICILLIN; CHLORAMPHENICOL; COTRIMOXAZOLE; HEPATITIS A VACCINE; PNEUMOCOCCUS VACCINE; TYPBAR; TYPHOID VACCINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ASIA; BANGLADESH; CLINICAL TRIAL; DRUG COST; DRUG FEVER; DRUG INDUCED HEADACHE; HEALTH CARE COST; HUMAN; INCIDENCE; INDIA; INFECTION PREVENTION; INJECTION SITE PAIN; PAKISTAN; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; SALMONELLA TYPHI; SINGLE DRUG DOSE; TYPHOID FEVER; UNSPECIFIED SIDE EFFECT; WORLD HEALTH ORGANIZATION;

BANGLADESH; CHINA; DRUG RESISTANCE, BACTERIAL; HUMANS; IMMUNITY, HERD; INDIA; PAKISTAN; POLYSACCHARIDES, BACTERIAL; SALMONELLA TYPHI; TRAVEL; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINATION;

EID: 77952191638     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.43     Document Type: Review

References (89)

1. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N. Engl. J. Med. 347(22), 1770-1782 (2002).
2. Akpede GO, Akenzua GI. Management of children with prolonged fever of unknown origin and difficulties in the management of fever of unknown origin in children in developing countries. Paediatr. Drugs 3(4), 247-262 (2001).
3. Butler T, Islam A, Kabir I, Jones PK. Patterns of morbidity and mortality in typhoid fever dependent on age and gender: review of 552 hospitalized patients with diarrhea. Rev. Infect. Dis. 13(1), 85-90 (1991).
4. Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet 366(9487), 749-762 (2005).
5. Levine MM, Black RE, Lanata C. Precise estimation of the numbers of chronic carriers of Salmonella Typhi in Santiago, Chile, an endemic area. J. Infect. Dis. 146(6), 724-726 (1982).
6. Michel R, Garnotel E, Spiegel A et al. Outbreak of typhoid fever in vaccinated members of the French Armed Forces in the Ivory Coast. Eur. J. Epidemiol. 20(7), 635-642 (2005).
7. Vollaard AM, Ali S, van Asten HA et al. Risk factors for typhoid and paratyphoid fever in Jakarta, Indonesia. JAMA 291(21), 2607-2615 (2004).
8. Ram PK, Naheed A, Brooks WA et al. Risk factors for typhoid fever in a slum in Dhaka, Bangladesh. Epidemiol. Infect. 135(3), 458-465 (2007).
9. Pfeiffer RW. Experimentelle Untersuchungen zur Frage der Schutzimpfung des Menschen gegen Typhus abdominalis. Dtsch. Med. Wochenschr. 22, 3 (1896).
10. Hawley PR, Simmons JS. The effectiveness of vaccines used for the prevention of typhoid fever in the United States Army and Navy. Am. J. Public Health Nations Health 24(7), 689-709 (1934).
11. Wright AE, Leishman WB. Remarks on the results which have been obtained by the antityphoid incoulations and on the methods which have been employed in the preparation of the vaccine. Brit. Med. J. 1, 8 (1900).
12. Siler JF, Dunham GC. Duration of immunity conferred by typhoid vaccine: results of re-vaccination by intracutaneous injection of typhoid vaccine. Am. J. Public Health Nations Health 29(2), 95-103 (1939).
13. Wahdan MH, Sippel JE, Mikhail IA et al. Controlled field trial of a typhoid vaccine prepared with a nonmotile mutant of Salmonella Typhi Ty2. Bull. World Health Organ. 52(1), 69-73 (1975).
14. Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull. World Health Organ. 72(6), 957-971 (1994).
15. Meyruey MH, Goudineau JA, Germain M. [Chloramphenicol-resistant typhoid fever in Saigon]. Nouv. Presse Med. 2(21), 1455 (1973).
16. Olarte J, Galindo E. Salmonella Typhi resistant to chloramphenicol, ampicillin, and other antimicrobial agents: strains isolated during an extensive typhoid fever epidemic in Mexico. Antimicrob. Agents Chemother. 4(6), 597-601 (1973).
17. Bhutta ZA, Naqvi SH, Razzaq RA, Farooqui BJ. Multidrug-resistant typhoid in children: presentation and clinical features. Rev. Infect. Dis. 13(5), 832-836 (1991).
18. Uwaydah AK, Matar I, Chacko KC, Davidson JC. The emergence of antimicrobial resistant Salmonella Typhi in Qatar: epidemiology and therapeutic implications. Trans. R. Soc. Trop. Med. Hyg. 85(6), 790-792 (1991).
19. Coovadia YM, Gathiram V, Bhamjee A et al. An outbreak of multiresistant Salmonella Typhi in South Africa. Q. J. Med. 82(298), 91-100 (1992).
20. Gupta B, Kumar R, Khurana S. Multi drug resistant Salmonella Typhi in Ludhiana (Punjab). Indian J. Pathol. Bacteriol. 36(1), 5-7 (1993).
21. Mirza SH, Beeching NJ, Hart CA. Multi-drug resistant typhoid: a global problem. J. Med. Microbiol. 44(5), 317-319 (1996).
22. Wahdan MH, Serie C, Cerisier Y, Sallam S, Germanier R. A controlled field trial of live Salmonella Typhi strain Ty 21a oral vaccine against typhoid: three-year results. J. Infect. Dis. 145(3), 292-295 (1982).
23. Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. Lancet 336(8720), 891-894 (1990). (Pubitemid 20351161)
24. Tacket CO, Ferreccio C, Robbins JB et al. Safety and immunogenicity of two Salmonella Typhi Vi capsular polysaccharide vaccines. J. Infect. Dis. 154(2), 342-345 (1986).
25. Tacket CO, Levine MM, Robbins JB. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever. Vaccine 6(4), 307-308 (1988).
26. Keitel WA, Bond NL, Zahradnik JM, Cramton TA, Robbins JB. Clinical and serological responses following primary and booster immunization with Salmonella Typhi Vi capsular polysaccharide vaccines. Vaccine 12(3), 195-199 (1994).
27. Plotkin SA, Bouveret-Le Cam N. A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch. Intern. Med. 155(21), 2293-2299 (1995).
28. Typhoid vaccines: WHO position paper. Wkly. Epidemiol. Rec. 83(6), 49-59 (2008).
29. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull. World Health Organ. 82(5), 346-353 (2004).
30. Saha SK, Baqui AH, Hanif M et al. Typhoid fever in Bangladesh: implications for vaccination policy. Pediatr. Infect. Dis. J. 20(5), 521-524 (2001).
31. Sinha A, Sazawal S, Kumar R et al. Typhoid fever in children aged less than 5 years. Lancet 354(9180), 734-737 (1999).
32. Siddiqui FJ, Rabbani F, Hasan R, Nizami SQ, Bhutta ZA. Typhoid fever in children: some epidemiological considerations from Karachi, Pakistan. Int. J. Infect. Dis. 10(3), 215-222 (2006).
33. Crump JA, Ram PK, Gupta SK, Miller MA, Mintz ED. Part I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005. Epidemiol. Infect. 136(4), 436-448 (2008).
34. Maskey AP, Basnyat B, Thwaites GE et al. Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003. Trans. R. Soc. Trop. Med. Hyg. 102(1), 91-95 (2008).
35. Brooks WA, Hossain A, Goswami D et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerging Infect. Dis. 11(2), 326-329 (2005).
36. Ochiai RL, Acosta CJ, Danovaro- Holliday MC et al. A study of typhoid fever in five Asian countries: disease burden and implications for controls. Bull. World Health Organ. 86(4), 260-268 (2008).
37. Vallenas C, Hernandez H, Kay B, Black R, Gotuzzo E. Efficacy of bone marrow, blood, stool and duodenal contents cultures for bacteriologic confirmation of typhoid fever in children. Pediatr. Infect. Dis. 4(5), 496-498 (1985).
38. Chang JE, Hernandez H, Yi A et al. [Hemoculture and bone marrow culture in children with typhoid fever]. Bol. Med. Hosp. Infant. Mex. 39(9), 614-616 (1982).
39. Gilman RH, Terminel M, Levine MM, Hernandez-Mendoza P, Hornick RB. Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella Typhi in typhoid fever. Lancet 1(7918), 1211-1213 (1975).
40. Woodward TE, Smadel JE et al. Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever. Ann. Intern. Med. 29(1), 131-134 (1948).
41. Chatterjee H, Jagdish S, Pai D et al. Changing trends in outcome of typhoid ileal perforations over three decades in Pondicherry. Trop. Gastroenterol. 22(3), 155-158 (2001).
42. Bahl R, Sinha A, Poulos C et al. Costs of illness due to typhoid fever in an Indian urban slum community: implications for vaccination policy. J. Health. Popul. Nutr. 22(3), 304-310 (2004).
43. Poulos C, Bahl R, Whittington D et al. A cost-benefit analysis of typhoid fever immunization programmes in an Indian urban slum community. J. Health. Popul. Nutr. 22(3), 311-321 (2004).
44. Felix A, Pitt M. A new antigen of B. typhosus. Lancet 224(5787), 6 (1934).
45. Szu SC, Li XR, Stone AL, Robbins JB. Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect. Immun. 59(12), 4555-4561 (1991).
46. Robbins JD, Robbins JB. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella Typhi. J. Infect. Dis. 150(3), 436-449 (1984).
47. Wong KH, Feeley JC, Northrup RS, Forlines ME. Vi antigen from Salmonella typhosa and immunity against typhoid fever. I. Isolation and immunologic properties in animals. Infect. Immun. 9(2), 348-353 (1974).
48. Felix A, Anderson ES. The immunizing potency of alcohol-killed and alcohol-preserved typhoid vaccine after storage for ten years. J. Hyg. (Lond.) 49(2-3), 288-298 (1951).
49. Zuckerman JN. A recently developed typhoid Vi polysaccharide vaccine: rationale and clinical profile. BioDrugs 15(Suppl. 1), 1-4 (2001).
50. Wang JY, Noriega FR, Galen JE, Barry E, Levine MM. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar Typhi oral vaccine strain CVD 909. Infect. Immun. 68(8), 4647-4652 (2000).
51. Landy M, Lamb E. Estimation of Vi antibody employing erythrocytes treated with purified Vi antigen. Proc. Soc. Exp. Biol. Med. 82(4), 593-598 (1953).
52. Lim SM, Jung HS, Kim MJ et al. Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea. J. Microbiol. Biotechnol. 17(4), 611-615 (2007).
53. Sabitha P, Prabha Adhikari MR, Chowdary A et al. Comparison of the immunogenicity and safety of two different brands of Salmonella Typhi Vi capsular polysaccharide vaccine. Indian J. Med. Sci. 58(4), 141-149 (2004).
54. Panchanathan V, Kumar S, Yeap W et al. Comparison of safety and immunogenicity of a Vi polysaccharide typhoid vaccine with a whole-cell killed vaccine in Malaysian Air Force recruits. Bull. World Health Organ. 79(9), 811-817 (2001).
55. Acharya IL, Lowe CU, Thapa R et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella Typhi. A preliminary report. N. Engl. J. Med. 317(18), 1101-1104 (1987).
56. Klugman KP, Gilbertson IT, Koornhof HJ et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 2(8569), 1165-1169 (1987).
57. Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella Typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14(5), 435-438 (1996).
58. Mirza NB, Wamola IA, Estambale BA, Mbithi E, Poillet M. Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya. East Afr. Med. J. 72(3), 162-164 (1995).
59. Overbosch D, Peyron F, Picot N et al. Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years. J. Travel Med. 12(6), 319-326 (2005).
60. Dumas R, Forrat R, Lang J, Farinelli T, Loutan L. Safety and immunogenicity of a new inactivated hepatitis A vaccine in concurrent administration with a typhoid fever vaccine or a typhoid fever + yellow fever vaccine. Adv. Ther. 14(4), 160-167 (1997).
61. Acosta CJ, Hong-Hui Y, Ning W et al. Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow-up. Vaccine 23(48-49), 5618-5623 (2005).
62. World Health Organization. Requirements for Vi polysaccharide typhoid vaccine (Requirements for Biological Substances No. 48). In: WHO Technical Report Series. WHO, Geneva, Switzerland (1994).
63. Zhou WZ, Koo HW, Wang XY et al. Revaccination with locally-produced Vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings. Pediatr. Infect. Dis. J. 26(11), 1001-1005 (2007).
64. Hessel L, Debois H, Fletcher M, Dumas R. Experience with Salmonella Typhi Vi capsular polysaccharide vaccine. Eur. J. Clin. Microbiol. Infect. Dis. 18(9), 609-620 (1999).
65. DeRoeck D, Ochiai RL, Yang J et al. Typhoid vaccination: the Asian experience. Expert Rev. Vaccines 7(5), 547-560 (2008).
66. Yang HH. Experience of school based vaccination in typhoid fever endemic area using Vi manufactured in China. Presented at: Typhoid Fever, A Neglected Disease: Towards a Vaccine Introduction Policy. Annecy, France, 2-4 April 2007
67. Yang J. Enteric Fever in South China: Guangxi Province. J. Infect. Dev. Ctries 2(4), 6 (2008).
68. Ochiai RL, Acosta CJ, Agtini M et al. The use of typhoid vaccines in Asia: the DOMI experience. Clin. Infect. Dis. 45(Suppl. 1), S34-S38 (2007).
69. Acosta CJ, Galindo CM, Ali M et al. A multi-country cluster randomized controlled effectiveness evaluation to accelerate the introduction of Vi polysaccharide typhoid vaccine in developing countries in Asia: rationale and design. Trop. Med. Int. Health 10(12), 1219-1228 (2005).
70. Yang J, Acosta CJ, Si GA et al. A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in Southeast China: a cluster-randomized trial. BMC Public Health 5, 49 (2005).
71. Agtini MD, Ochiai RL, Soeharno R et al. Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform. Public Health 120(11), 1081-1087 (2006).
72. Thiem VD, Danovaro-Holliday MC, Canh do G et al. The feasibility of a school-based Vi polysaccharide vaccine mass immunization campaign in Hue City, central Vietnam: streamlining a typhoid fever preventive strategy. Southeast Asian J. Trop. Med. Public Health 37(3), 515-522 (2006).
73. Khan MI, Ochiai RL, Hamza HB et al. Lessons and implications from a mass immunization campaign in squatter settlements of Karachi, Pakistan: an experience from a cluster-randomized double-blinded vaccine trial [NCT00125047]. Trials 7, 17 (2006).
74. Yang HH, Kilgore PE, Yang LH et al. An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. J. Infect. Dis. 183(12), 1775-1780 (2001).
75. Sur D, Ochiai RL, Bhattacharya SK et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N. Engl. J. Med. 361(4), 335-344 (2009).
76. DeRoeck D, Clemens JD, Nyamete A, Mahoney RT. Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine 23(21), 2762-2774 (2005).
77. Chen X, Stanton B, Wang X et al. Differences in perception of dysentery and enteric fever and willingness to receive vaccines among rural residents in China. Vaccine 24(5), 561-571 (2006).
78. Do GC, Whittington D, Le TK et al. Household demand for typhoid fever vaccines in Hue, Vietnam. Health Policy Plan. 21(3), 241-255 (2006).
79. Whittington D, Sur D, Cook J et al. Rethinking cholera and typhoid vaccination policies for the poor: private demand in Kolkata, India. World Dev. 37(2), 399-409 (2009).
80. Cook J, Jeuland M, Whittington D et al. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine 26(50), 6305-6316 (2008).
81. Uneke CJ. Concurrent malaria and typhoid fever in the tropics: the diagnostic challenges and public health implications. J. Vector Borne Dis. 45(2), 133-142 (2008).
82. Saha MR, Ramamurthy T, Dutta P, Mitra U. Emergence of Salmonella Typhi Vi antigen-negative strains in an epidemic of multidrug-resistant typhoid fever cases in Calcutta, India. Natl Med. J. India 13(3), 164 (2000).
83. Arya SC, Agarwal N. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N. Engl. J. Med. 361(22), 2191 (2009).
84. Baker S, Sarwar Y, Aziz H et al. Detection of Vi-negative Salmonella enterica serovar Typhi in the peripheral blood of patients with typhoid fever in the Faisalabad region of Pakistan. J. Clin. Microbiol. 43(9), 4418-4425 (2005).
85. Wain J, House D, Zafar A et al. Vi antigen expression in Salmonella enterica serovar Typhi clinical isolates from Pakistan. J. Clin. Microbiol. 43(3), 1158-1165 (2005).
86. Meeting of the Immunization Strategic Advisory Group of Experts, November 2007 - conclusions and recommendations. Wkly. Epidemiol. Rec. 83(1), 1-15 (2008).
87. Sur D, Manna B, Chakrabarty N et al. Vaccine desirability during an effectiveness trial of the typhoid fever polysaccharide Vi vaccine, Kolkata India. Hum. Vaccin. 5(9), 614-620 (2009).
88. Lin FY, Ho VA, Khiem HB et al. The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 344(17), 1263-1269 (2001).
89. Lanh MN, Bay PV, Ho VA et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N. Engl. J. Med. 349(14), 1390-1391 (2003).